Abstract
Serious mental illness imposes a significant burden on individuals and society. Individuals living with serious mental illness have worse expected health, education, and career outcomes. And while treatments do exist, pharmaceutical innovation in this area has lagged behind many other disease areas, and there is an important need for new treatments. This report describes barriers that have limited innovation in developing new drugs for serious mental illness, including science, research, regulatory, and health system barriers, and presents policies that may incentivize investment in this area.